The Cauchy problem of the Klein-Gordon-Zakharov equation in three dimensional space is considered. It is shown that it is globally well-posed in energy space H^1 × L^2 × L^2 ×...The Cauchy problem of the Klein-Gordon-Zakharov equation in three dimensional space is considered. It is shown that it is globally well-posed in energy space H^1 × L^2 × L^2 × H^-1 if small initial data （u0 （x）, u1 （x）, n0 （x）, n1 （x）） ∈ （H^1 ×L^2× L^2 × H^-1）. It answers an open problem： Is it globally well-posed in energy space H^1 × L^2 × L^2 × H^-1 for 3D Klein-Gordon- Zakharov equation with small initial data [1, 2]？ The method in this article combines the linear property of the equation （ dispersive property） with nonlinear property of the equation （energy inequalities）. We mainly extend the spaces F^s and N^3 in one dimension [3] to higher dimension.展开更多
In this paper,the authors consider the local well-posedness for the derivative Schrödinger equation in higher dimension ut-iΔu+|u|^(2)(→γ·▽u)+u^(2)(→λ·▽-u)=0,(x,t)∈R^(n)×R,→γ,→λ∈R^(n);...In this paper,the authors consider the local well-posedness for the derivative Schrödinger equation in higher dimension ut-iΔu+|u|^(2)(→γ·▽u)+u^(2)(→λ·▽-u)=0,(x,t)∈R^(n)×R,→γ,→λ∈R^(n);n≥2 It is shown that the Cauchy problem of the derivative Schrödinger equation in higher dimension is locally well-posed in H^(s)(R^(n))(s>n/2)for any large initial data.Thus this result can compare with that in one dimension except for the endpoint space H^(n/2).展开更多
Purpose:Olecranon fractures are particularly vulnerable to distraction and subsequent fracture dislocation due to the high tensile forces.Surgical treatment aims at reducing the fracture and restoring the anatomical j...Purpose:Olecranon fractures are particularly vulnerable to distraction and subsequent fracture dislocation due to the high tensile forces.Surgical treatment aims at reducing the fracture and restoring the anatomical joint surface condition,as well as neutralizing the strain inhibiting fracture healing.The XS nail®(Intercus GmbH,Bad Blankenberg,Germany),an intramedullary implant exerting compression across the entire fracture surface,unlike plates,leaves a minimal extra-cortical profile,and can be secured with threaded locking wires,thereby retaining the anatomical reduction without displacement or steps within the articular surface,which was often found in tension band wiring.After encouraging initial results,the long-term outcome was assessed.Methods:This retrospective study evaluated the long-term outcome of patients surgically treated at our trauma center between January 2002 and December 2005 using the XS nail®.Patients over the age of 18 years eligible for the study must have undergone surgery for isolated,recent(less than 14 days)traumatic olecranon fractures,without concomitant injuries to the ipsilateral elbow and forearm.Further exclusion criteria were pseudarthrosis,re-fractures and osteotomy for distal humerus surgery,as well as polytraumatized patients unable to aid in their own recovery.Data were retrospectively gathered by standardised questionnaire and patient records,as well as surgery and anesthesiology reports.Data analysis was performed using Microsoft Office Excel?2016.Results:There were 32 patients,13 males(mean age 49.0 years)and 19 females(mean age 68.9 years)with 11 Schatzkers type D,7 each type A and C,5 type B and 2 type E at an average of 55.2 months,all showing complete consolidation.Of them,6 patients had a loss of range of motion with more than 10°in the sagittal plane,and only 1 patient exceeded 10°reduction of supination.Twenty-five patients reported being pain-free under all circumstances,and all but 2 patients(93.75%)had returned to their previous activity level.The average d展开更多
Background XS0601, consisting of active ingredients （Chuangxiongol and paeoniflorin）, has been shown to inhibit arterial neointimal hyperplasia in animal models and in preliminary human studies. The objective of thi...Background XS0601, consisting of active ingredients （Chuangxiongol and paeoniflorin）, has been shown to inhibit arterial neointimal hyperplasia in animal models and in preliminary human studies. The objective of this study was to evaluate the safety and efficacy of XS0601 in preventing restenosis following percutaneous coronary intervention （PCI）. Methods A multi-center, randomized, double-blind, placebo-controlled trial was conducted. A total of 335 patients were randomized into treatment with the oral administration of XS0601, or a placebo for 6 months after successful PCI. Angiographic follow-up was scheduled at 6 months, and clinical follow-ups performed at 1, 3 and 6 months after PCI. The primary end point was angiographic restenosis. The secondary end points were the combined incidence of death, target lesion nonfatal myocardial infarction, repeat angioplasty, and coronary artery bypass graft surgery. Results A total of 308 patients （91.9%） completed the study and 145 cases （47.1%） received angiographic follow-up. The restenosis rates were significantly reduced in the XS0601 group as compared with the placebo group （26.0% vs. 47.2%, P 〈 0.05）, and the minimum lumen diameter （MLD） was greater [（2.08 ± 0.89） mm for XS0601 vs. （1.73 ± 0.94） mm for placebo, P 〈 0.05]. XS0601 also significantly reduced the combined incidence of major adverse cardiac event （10.4% in the XS0601 group vs. 22.7% in the placebo group, P 〈 0.05）. The incidence of recurrent angina at 3 and 6 months after PCI was also significantly reduced in XS0601 group （7.1% and 11.0%） as compared with those in placebo group （19.5% and 42.9%） （P 〈 0.05）. No significant side effects occurred within the 6-month follow-up period in the XS0601 group.Conclusion Administration of XS0601 for 6 months is demonstrated to be safe and effective in reducing restenosis in post-PCI patients.展开更多
文摘The Cauchy problem of the Klein-Gordon-Zakharov equation in three dimensional space is considered. It is shown that it is globally well-posed in energy space H^1 × L^2 × L^2 × H^-1 if small initial data （u0 （x）, u1 （x）, n0 （x）, n1 （x）） ∈ （H^1 ×L^2× L^2 × H^-1）. It answers an open problem： Is it globally well-posed in energy space H^1 × L^2 × L^2 × H^-1 for 3D Klein-Gordon- Zakharov equation with small initial data [1, 2]？ The method in this article combines the linear property of the equation （ dispersive property） with nonlinear property of the equation （energy inequalities）. We mainly extend the spaces F^s and N^3 in one dimension [3] to higher dimension.
文摘In this paper,the authors consider the local well-posedness for the derivative Schrödinger equation in higher dimension ut-iΔu+|u|^(2)(→γ·▽u)+u^(2)(→λ·▽-u)=0,(x,t)∈R^(n)×R,→γ,→λ∈R^(n);n≥2 It is shown that the Cauchy problem of the derivative Schrödinger equation in higher dimension is locally well-posed in H^(s)(R^(n))(s>n/2)for any large initial data.Thus this result can compare with that in one dimension except for the endpoint space H^(n/2).
文摘Purpose:Olecranon fractures are particularly vulnerable to distraction and subsequent fracture dislocation due to the high tensile forces.Surgical treatment aims at reducing the fracture and restoring the anatomical joint surface condition,as well as neutralizing the strain inhibiting fracture healing.The XS nail®(Intercus GmbH,Bad Blankenberg,Germany),an intramedullary implant exerting compression across the entire fracture surface,unlike plates,leaves a minimal extra-cortical profile,and can be secured with threaded locking wires,thereby retaining the anatomical reduction without displacement or steps within the articular surface,which was often found in tension band wiring.After encouraging initial results,the long-term outcome was assessed.Methods:This retrospective study evaluated the long-term outcome of patients surgically treated at our trauma center between January 2002 and December 2005 using the XS nail®.Patients over the age of 18 years eligible for the study must have undergone surgery for isolated,recent(less than 14 days)traumatic olecranon fractures,without concomitant injuries to the ipsilateral elbow and forearm.Further exclusion criteria were pseudarthrosis,re-fractures and osteotomy for distal humerus surgery,as well as polytraumatized patients unable to aid in their own recovery.Data were retrospectively gathered by standardised questionnaire and patient records,as well as surgery and anesthesiology reports.Data analysis was performed using Microsoft Office Excel?2016.Results:There were 32 patients,13 males(mean age 49.0 years)and 19 females(mean age 68.9 years)with 11 Schatzkers type D,7 each type A and C,5 type B and 2 type E at an average of 55.2 months,all showing complete consolidation.Of them,6 patients had a loss of range of motion with more than 10°in the sagittal plane,and only 1 patient exceeded 10°reduction of supination.Twenty-five patients reported being pain-free under all circumstances,and all but 2 patients(93.75%)had returned to their previous activity level.The average d
基金THIS STUDY WAS SUPPORTED BY GRANTS FROM NATIONAL TENTH FIVE-YEAR PROJECTS PLAN (NO. 2001BA701A20)
文摘Background XS0601, consisting of active ingredients （Chuangxiongol and paeoniflorin）, has been shown to inhibit arterial neointimal hyperplasia in animal models and in preliminary human studies. The objective of this study was to evaluate the safety and efficacy of XS0601 in preventing restenosis following percutaneous coronary intervention （PCI）. Methods A multi-center, randomized, double-blind, placebo-controlled trial was conducted. A total of 335 patients were randomized into treatment with the oral administration of XS0601, or a placebo for 6 months after successful PCI. Angiographic follow-up was scheduled at 6 months, and clinical follow-ups performed at 1, 3 and 6 months after PCI. The primary end point was angiographic restenosis. The secondary end points were the combined incidence of death, target lesion nonfatal myocardial infarction, repeat angioplasty, and coronary artery bypass graft surgery. Results A total of 308 patients （91.9%） completed the study and 145 cases （47.1%） received angiographic follow-up. The restenosis rates were significantly reduced in the XS0601 group as compared with the placebo group （26.0% vs. 47.2%, P 〈 0.05）, and the minimum lumen diameter （MLD） was greater [（2.08 ± 0.89） mm for XS0601 vs. （1.73 ± 0.94） mm for placebo, P 〈 0.05]. XS0601 also significantly reduced the combined incidence of major adverse cardiac event （10.4% in the XS0601 group vs. 22.7% in the placebo group, P 〈 0.05）. The incidence of recurrent angina at 3 and 6 months after PCI was also significantly reduced in XS0601 group （7.1% and 11.0%） as compared with those in placebo group （19.5% and 42.9%） （P 〈 0.05）. No significant side effects occurred within the 6-month follow-up period in the XS0601 group.Conclusion Administration of XS0601 for 6 months is demonstrated to be safe and effective in reducing restenosis in post-PCI patients.
